Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease

Table 4

ESC Anticoagulation regimen in patients with high bleeding risk after stent implantation [1].

Setting stent	Anticoagulation (HAS-BLED ≥ 3)
Elective BMS^#	2–4 weeks: VKA + aspirin + clopidogrel; Lifelong: VKA
ACS BMS^#	4 weeks: VKA + aspirin+ clopidogrel; Up to 12th month: VKA + clopidogrel (oraspirin); Lifelong: VKA

ACS: acute coronary syndrome, BMS: bare metal stent, DES: drug eluting stent, VKA: vitamin K-antagonist, ^#DES should be avoided as far as possible; if used, triple therapy might be prolonged to 3–6 months. The INR should be adjusted according to concomitant antiplatelet therapy (2-3 in vitamin K-antagonist monotherapy and 2–2.5 in case of concomitant antiplatelet therapy).